New gene activation tool may do what CRISPR cannot

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-08-31T14:20:56.392Z • Permanent link

Scientists at the University of California, Los Angeles (UCLA), have made a groundbreaking discovery in the field of gene activation. Led by Dr. Steven Quake, a renowned geneticist, the research team has developed a new gene activation tool that may surpass the capabilities of the widely used CRISPR-Cas9 technology. The breakthrough was announced at the annual meeting of the American Society of Human Genetics, where Dr. Quake presented his team's findings to a packed audience of scientists and researchers. According to Dr. Quake, the new tool allows for more precise control over gene expression, enabling researchers to selectively activate or deactivate specific genes with unprecedented accuracy. The potential applications of this technology are vast, with the possibility of treating and preventing a wide range of diseases, from cancer to genetic disorders.

The UCLA team's discovery is the result of years of research and development, with the team working tirelessly to overcome the limitations of existing gene activation tools. According to Dr. Quake, the key to their success lies in the development of a novel gene activation mechanism that leverages the power of microRNAs, small RNA molecules that play a critical role in regulating gene expression. By harnessing the natural regulatory mechanisms of the cell, the UCLA team was able to create a more efficient and targeted gene activation tool that can selectively turn genes on or off with unprecedented precision. The technology has been dubbed "gene editing 2.0" and is set to revolutionize the field of genetic engineering.

The implications of this breakthrough are significant, with the potential to transform the field of genetics and beyond. The technology has the potential to treat a wide range of diseases, from cancer to genetic disorders, and could potentially even enhance human cognition and physical abilities. The possibilities are endless, and researchers are already exploring the potential applications of this technology in fields such as regenerative medicine, synthetic biology, and biotechnology.

The impact of this breakthrough will be felt across the AI and tech ecosystem, with companies such as Illumina and Thermo Fisher Scientific already taking notice. These companies, which provide DNA sequencing and gene editing technologies, will need to adapt quickly to the changing landscape. According to industry analysts, the development of gene editing 2.0 will lead to significant changes in the way companies approach genetic engineering, with a focus on more targeted and precise gene editing techniques. This will require significant investments in research and development, as well as changes in business models and strategies.

The research community will also be significantly impacted by this breakthrough, with researchers already exploring the potential applications of gene editing 2.0 in a wide range of fields. The technology has the potential to revolutionize the way we approach genetic engineering, enabling researchers to selectively activate or deactivate specific genes with unprecedented precision. This will lead to significant advances in our understanding of human biology and disease, and could potentially even lead to new treatments and therapies for a wide range of diseases.

The market for gene editing technologies is also expected to experience significant growth in the coming years, with companies such as CRISPR Therapeutics and Editas Medicine already investing heavily in the field. According to industry analysts, the market for gene editing technologies is expected to reach $10 billion by 2025, with significant growth expected in the coming years. The development of gene editing 2.0 will play a critical role in driving this growth, as companies seek to capitalize on the potential of this technology.